This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

OKYO Pharma Valuation

Q: What is the Fair Price of OK10 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

OK10 (€1.36) is trading below our estimate of [[fair value]] (€9.4)

Is OK10 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OK10 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OK10 (€1.36) is trading below our estimate of fair value (€9.4)

Significantly Below Fair Value: OK10 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OK10?

Other financial metrics that can be useful for relative valuation.

The above table shows the n/a ratio for OK10. This is calculated by dividing OK10's market cap by their current preferred multiple.
What is OK10's n/a Ratio?
n/a	0x
n/a	n/a
Market Cap	UK£32.70m

OK10 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-2.3x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does OK10's PB Ratio compare to its peers?

The above table shows the PB ratio for OK10 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	15x
VSC 4SC	54.7x	n/a	€60.0m
MDG1 Medigene	1.6x	-4.1%	€31.2m
2INV 2invest	1x	n/a	€60.4m
HPHA Heidelberg Pharma	2.7x	-31.2%	€111.4m
OK10 OKYO Pharma	n/a	109.7%	€41.7m

Price-To-Book vs Peers: OK10 has negative equity and a Price-To-Book Ratio (-15.9x) compared to the peer average (4.3x).

Price to Earnings Ratio vs Industry

How does OK10's PE Ratio compare vs other companies in the DE Biotechs Industry?

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

Fetching data

0 Companies	Price / Earnings	Estimated Growth	Market Cap
Industry Avg.	n/a	35.4%
	n/a	n/a	n/a

No more companies

Price-To-Book vs Industry: OK10 has negative equity and a Price-To-Book Ratio (-15.9x) compared to the European Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is OK10's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OK10 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	-15.9x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate OK10's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.